|
NYBA News |
Member News
|
Press Release
|
| |
|
|
News type
|
|
Regeneron Pharmaceuticals, Inc. |
|
Headline:
Regeneron Announces EYLEA(TM) (aflibercept ophthalmic solution) Receives Unanimous Recommendation for Approval for Treatment of Wet AMD from FDA Advisory Committee
Date:
16-Jun-2011
News Type:
Member News
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the Dermatologic
and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has
voted unanimously to recommend that the FDA approve EYLEA™, also known as VEGF
Trap-Eye, for the treatment of the neovascular form of age-related macular degeneration
(wet AMD) at a dose of 2 milligrams (mg) ever ...
Details »
|
|
| |
|
Kadmon Pharmaceuticals LLC |
|
Headline:
Kadmon Pharmaceuticals and Nano Terra Announce Worldwide Exclusive Licensing Agreement for Three Novel Product Candidates
Date:
01-Jun-2011
News Type:
Member News
Novel ROCK2 Inhibitor Data Suggests Potential Activity in ...
Details »
|
|
| |
|
Litron Laboratories |
|
Headline:
Litron Receives Second Year of SBIR Funding to Study Tools to Measure Radiation Exposure
Date:
01-Jun-2011
News Type:
Member News
Litron Laboratory scientists have obtained continued funding after a successful first year
completion of a Small Busin ...
Details »
|
|
| |
|
Clinilabs, Inc. |
|
Headline:
Clinilabs Selected for a Phase 1 Study of An Investigational Patch Medication
Date:
24-May-2011
News Type:
Member News
Clinilabs, a full-service contract research organization that provides early-stage and
specialty clinical drug development services to industry, announced today that they have
been selected to conduct a Phase 1 clinical res ...
Details »
|
|
| |
|
Kinex Pharmaceuticals |
|
Headline:
The Oishei Foundation Makes Investment in Kinex Pharmaceuticals
Date:
24-May-2011
News Type:
Member News
Kinex Pharmaceuticals, LLC announced today that The Oishei Foundation has made an
investment in the current Series A1 round of Financing.
The John R. Oishei Foundation is the area's largest private found ...
Details »
|
|
| |
|
Regeneron Pharmaceuticals, Inc. |
|
Headline:
FDA Schedules Advisory Committee Meeting to Discuss BLA for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
Date:
23-May-2011
News Type:
Member News
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that the U.S. Food and Drug
Administration (FDA) has informed the company that it has scheduled a Dermatologic and
Ophthalmic Drugs Advisory Committee Meeting to be held on Ju ...
Details »
|
|
| |
|
Pfizer Inc. |
|
Headline:
Adding Inspra® (eplerenone) To Standard Therapy Reduces The Incidence Of New Onset Atrial Fibrillation/Flutter (AF/F) In Patients With Systolic Heart Failure, Sub-Analysis Shows
Date:
22-May-2011
News Type:
Member News
Findings from the Eplerenone in Mild Patients Hospitalization And Survival Study in Heart
Failure (EMPHASIS-HF)
...
Details »
|
|
| |
|
Progenics Pharmaceuticals, Inc. |
|
Headline:
Progenics Announces Results of Methylnaltrexone Phase 3 Safety Study in Chronic, Non-Malignant Pain Patients
Date:
20-May-2011
News Type:
Member News
Drug Generally Safe and Well Tolerated With Durable Clinical Responses in One-Year Study
...
Details »
|
|
| |
|
Pfizer Inc. |
|
Headline:
ELIQUIS® (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement
Date:
20-May-2011
News Type:
Member News
ELIQUIS demonstrated superior efficacy versus enoxaparin 40 mg once daily without
increased bleeding
ELIQUIS is the only oral anticoagulant ...
Details »
|
|
| |
|
Amgen, Inc. |
|
Headline:
Amgen Receives CHMP Positive Opinion for XGEVA(TM) (Denosumab) in the European Union
Date:
20-May-2011
News Type:
Member News
Amgen (Nasdaq: AMGN) today announced that the Committee for Medicinal Products for Human
Use (CHMP) of the European Medicines Agency (EMA) has recommended a positive opinion for
the marketing authorization of XGEVA(TM) (denosumab) for the prevention of
skeletal-related events (pathological fracture, radiation to b ...
Details »
|
|
| |
|
|
